Lyra Therapeutics Inc's Customers Performance

Name: Lyra Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

LYRA

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


LYRA's Source of Revenues		During the corresponding time, Lyra Therapeutics Inc saw a revenue deteriorated by -96.65 % year on year, sequentially revenue fell by -72 %. While revenue at the Lyra Therapeutics Inc 's corporate clients • List of LYRA Customers

for the same period Lyra Therapeutics Inc revnue deteriorated by -96.65 % year on year, sequentially revenue fell by -72 %.

• List of LYRA Customers

Lyra Therapeutics Inc's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Lyra Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Lyra Therapeutics Inc Contracts

The Road Not Taken: Lyra Therapeutics’ Unexpected Outcome from Phase 3 Clinical Trial and its Ripple Effect.

In an unexpected turn of events, Lyra Therapeutics reported that its Phase 3 ENLIGHTEN 1 Trial for LYR-210 failed to meet its primary endpoint. LYR-210, an innovative therapy for chronic rhinosinusitis, a debilitating condition characterized by inflammation of the nose and sinuses, has been under research and development for years. The trial, which sought to evaluate LYR-210 s efficacy vis-à-vis the treatment of chronic rhinosinusitis, recently concluded without fulfilling its primary endpoint, signifying a setback for Lyra Therapeutics, not only from a financial perspective but also in terms of their strategic roadmap.Unraveling the ENLIGHTEN 1 trial, it was focused on chronic rhinosinusitis patients witho...

LYRA's Stock Performance relative to it's Customers

LYRA's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Lyra Therapeutics Inc	0.31	0.60	-32.95	27
SUBTOTAL	0.00	0.00	0.00	-

Sources: Lyra Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Lyra Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Lyra Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.